Deep Longevity
Latest round
- Series A
Last raised
- Jul 2020
Total raised
- Undisclosed
Investors
- 6
About Deep Longevity
Deep Longevity, Ltd.Founded in 2020 and headquartered in San Diego, US, Deep Longevity, Ltd. specializes in health technology focused on aging assessments. The company has engaged in 2 deals, with the most recent deal occurring on September 2, 2020, when Regent Pacific Group Limited acquired Deep Longevity, Ltd. Financial terms of the acquisition were not disclosed.Deep Longevity specializes in advanced health technology, focusing primarily on its suite of aging clocks, which include Blood Age, Mind Age, Biometric Age, and Epigenetic Age. These products analyze various biological and psychological parameters, providing users with personalized health insights aimed at preventive care and early interventions. The aging clocks utilize comprehensive data from blood tests, DNA, and microbiome analyses, along with psychological surveys, to deliver precise assessments of individuals' biological age and health status. Targeted towards both enterprise clients and individual users, the company collaborates with universities, hospitals, and healthcare providers globally, including markets in North America, Europe, and Asia-Pacific.Deep Longevity's revenue model is centered around a Software as a Service (SaaS) framework, providing clients access to its aging clock platforms, SenoClock and SenoClock Gold. These platforms facilitate the generation of Biological Age predictions and Health Summary Reports for enterprise customers, including insurance companies, healthcare providers, and wellness programs. Transactions typically involve subscription agreements, where clients pay for access to the platforms and specific features that cater to their organizational needs. The company’s flagship products are integrated into these subscription services, allowing users to gain insights into their health based on specific assessments made by the aging clocks.Deep Longevity is focused on expanding its product offerings and market reach. Upcoming enhancements to the aging clock platforms are being designed, with new features aimed at improving user experience expected to launch in late 2023. The company plans to enter new geographical markets, particularly targeting regions in Asia-Pacific and Europe by the end of 2024.
Who invested in Deep Longevity
6 investors across 1 round
See all investors in Deep Longevity
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 14, 2020
Amount
Undisclosed
Investors
Questions about Deep Longevity
Who invested in Deep Longevity?
Deep Longevity has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Deep Longevity raised?
Deep Longevity has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Deep Longevity last raise money?
Deep Longevity's most recent round on record is a Series A, in Jul 2020.
What does Deep Longevity do?
Deep Longevity is a biotechnology company.
Where is Deep Longevity headquartered?
Deep Longevity is headquartered in San Diego, US.
Which VCs invest in companies like Deep Longevity?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Deep Longevity's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Deep Longevity? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.